yohimbine has been researched along with Disease Exacerbation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, K; Shimokawa, T; Yamagata, M; Yoneda, K | 1 |
| Bruzzone, A; Gass, H; Lanari, C; Lüthy, IA; Piñero, CP; Rojas, P; Romanato, M | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Peggs, D | 1 |
3 other study(ies) available for yohimbine and Disease Exacerbation
| Article | Year |
|---|---|
Inhibition of α
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progression; Epidermolysis Bullosa; Fibrosis; Hydralazine; Male; Nephrectomy; Norepinephrine; Periodontal Diseases; Photosensitivity Disorders; Proteinuria; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Yohimbine | 2021 |
α(2)-Adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Breast Neoplasms; Catecholamines; Cell Line; Cell Line, Tumor; Cell Proliferation; Clonidine; Disease Progression; Epithelial Cells; Female; Fibroblasts; Humans; Immunohistochemistry; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, Adrenergic, alpha-2; Stromal Cells; Yohimbine | 2011 |
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; Brain; Callithrix; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesias; Female; Idazoxan; Levodopa; Male; Receptors, Adrenergic, alpha-2; Time Factors; Yohimbine | 1999 |